Skip to main content
SpringerLink
Log in
Book cover

Hypertension and Cardiovascular Disease pp 261–277Cite as

Follow-Up of the Hypertensive Patients with Cardiovascular Disease

  • Chapter
  • First Online:

  • 1777 Accesses

Abstract

Arterial hypertension is one of the most important independent risk factor for cardiovascular (CV) diseases [1]. Subjects with hypertension are exposed to a high risk of coronary artery disease (CHD), stroke, peripheral artery disease, heart failure, kidney disease and a number of “soft” adverse manifestation of CV disease, including transitory ischemic attack, atrial fibrillation and other supraventricular arrhythmias [2, 3].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275(20):1571–6.

    Article  CAS  PubMed  Google Scholar 

  2. The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience. The Hypertension Detection and Follow-up Program Cooperative Research Group. Circulation. 1984;70(6):996–1003.

    Google Scholar 

  3. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007.

    Google Scholar 

  4. Fagard R. Hypertensive heart disease: pathophysiology and clinical and prognostic consequences. J Cardiovasc Pharmacol. 1992;19 Suppl 5:S59–66.

    Article  PubMed  Google Scholar 

  5. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993;88(4 Pt 1):1444–55.

    Article  CAS  PubMed  Google Scholar 

  6. de Simone G, Daniels SR, Kimball TR, Roman MJ, Romano C, Chinali M, et al. Evaluation of concentric left ventricular geometry in humans: evidence for age-related systematic underestimation. Hypertension. 2005;45(1):64–8.

    Article  PubMed  Google Scholar 

  7. Casalnuovo G, Gerdts E, de Simone G, Izzo R, De Marco M, Giudice R, et al. Arterial stiffness is associated with carotid atherosclerosis in hypertensive patients (The Campania Salute Network). Am J Hypertens. 2012;25(7):739–45.

    Google Scholar 

  8. de Simone G, Izzo R, Aurigemma GP, De Marco M, Rozza F, Trimarco V, et al. Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities. J Hypertens. 2015;33(4):745–54.

    Article  PubMed  Google Scholar 

  9. Tsao CW, Gona PN, Salton CJ, Chuang ML, Levy D, Manning WJ, et al. Left ventricular structure and risk of cardiovascular events: a Framingham Heart Study Cardiac Magnetic Resonance Study. J Am Heart Assoc. 2015;4(9):e002188.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Armstrong AC, Jacobs Jr DR, Gidding SS, Colangelo LA, Gjesdal O, Lewis CE, et al. Framingham score and LV mass predict events in young adults: CARDIA study. Int J Cardiol. 2014;172(2):350–5.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010;31(7):883–91.

    Article  PubMed  Google Scholar 

  12. Khouri MG, Peshock RM, Ayers CR, de Lemos JA, Drazner MH. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study. Circ Cardiovasc Imaging. 2010;3(2):164–71.

    Article  PubMed  Google Scholar 

  13. Zile MR, Gaasch WH, Patel K, Aban IB, Ahmed A. Adverse left ventricular remodeling in community-dwelling older adults predicts incident heart failure and mortality. JACC Heart Fail. 2014;2(5):512–22.

    Article  PubMed  Google Scholar 

  14. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.

    Article  CAS  PubMed  Google Scholar 

  15. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14–26.

    Article  Google Scholar 

  16. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.

    Article  CAS  PubMed  Google Scholar 

  17. WHO. Prevention of cardiovascular disease (CVDs): pocket guidelines for assessment and management of CVD risk. WHO library Cataloguing-in-Publication Data, editor. Geneva; 2007.

    Google Scholar 

  18. van Holten TC, Waanders LF, de Groot PG, Vissers J, Hoefer IE, Pasterkamp G, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One. 2013;8(4):e62080.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Tzoulaki I, Siontis KC, Ioannidis JP. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ. 2011;343:d6829.

    Google Scholar 

  20. Miller J, Kinni H, Lewandowski C, Nowak R, Levy P. Management of hypertension in stroke. Ann Emerg Med. 2014;64(3):248–55.

    Article  PubMed  Google Scholar 

  21. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.

    Article  CAS  PubMed  Google Scholar 

  22. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374(9689):525–33.

    Article  PubMed  Google Scholar 

  23. Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

    Article  CAS  PubMed  Google Scholar 

  24. Rosendorff C. Treatment of hypertension in patients with coronary artery disease. A case-based summary of the 2015 AHA/ACC/ASH scientific statement. Am J Med. 2015;(15):10.

    Google Scholar 

  25. de Simone G, Izzo R, Verdecchia P. Are observational studies more informative than randomized controlled trials in hypertension? Pro side of the argument. Hypertension. 2013;62(3):463–9.

    Article  PubMed  Google Scholar 

  26. Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13(2):217–24.

    PubMed  PubMed Central  Google Scholar 

  27. Kaplan NM. Morning surge in blood pressure. Circulation. 2003;107(10):1347.

    Article  PubMed  Google Scholar 

  28. Coleman AJ, Steel SD, Ashworth M, Vowler SL, Shennan A. Accuracy of the pressure scale of sphygmomanometers in clinical use within primary care. Blood Press Monit. 2005;10(4):181–8.

    Article  PubMed  Google Scholar 

  29. Beevers G, Lip GY, O’Brien E. ABC of hypertension. Blood pressure measurement. Part I-sphygmomanometry: factors common to all techniques. BMJ. 2001;322(7292):981–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ohkubo T, Metoki H, Imai Y. Prognostic significance of morning surge in blood pressure: which definition, which outcome? Blood Press Monit. 2008;13(3):161–2.

    Article  PubMed  Google Scholar 

  31. White WB, Giles T, Bakris GL, Neutel JM, Davidai G, Weber MA. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006;151(1):176–84.

    Article  CAS  PubMed  Google Scholar 

  32. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.

    Google Scholar 

  33. Kannel WB, Brand N, Skinner Jr JJ, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med. 1967;67(1):48–59.

    Article  CAS  PubMed  Google Scholar 

  34. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment. J Clin Hypertens. 2013;15(1):14–33.

    Article  CAS  Google Scholar 

  35. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(1 Pt 2):3S–10.

    Article  CAS  PubMed  Google Scholar 

  36. Fujita M, Hata A. Sex and age differences in the effect of obesity on incidence of hypertension in the Japanese population: a large historical cohort study. J Am Soc Hypertens. 2014;8(1):64–70.

    Article  PubMed  Google Scholar 

  37. de Simone G, Devereux RB, Chinali M, Roman MJ, Best LG, Welty TK, et al. Risk factors for arterial hypertension in adults with initial optimal blood pressure: the Strong Heart Study. Hypertension. 2006;47(2):162–7.

    Article  PubMed  Google Scholar 

  38. Chinali M, de Simone G, Roman MJ, Lee ET, Best LG, Howard BV, et al. Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol. 2006;47(11):2267–73.

    Article  PubMed  Google Scholar 

  39. de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens. 2002;20(2):323–31.

    Article  PubMed  Google Scholar 

  40. Arcucci O, de Simone G, Izzo R, Rozza F, Chinali M, Rao MA, et al. Association of suboptimal blood pressure control with body size and metabolic abnormalities. J Hypertens. 2007;25:2296–300.

    Article  CAS  PubMed  Google Scholar 

  41. De Marco M, de Simone G, Izzo R, Mancusi C, Sforza A, Giudice R, et al. Classes of antihypertensive medications and blood pressure control in relation to metabolic risk factors. J Hypertens. 2012;30(1):188–93.

    Article  PubMed  Google Scholar 

  42. de Simone G, Okin PM, Gerdts E, Olsen MH, Wachtell K, Hille DA, et al. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutr Metab Cardiovasc Dis. 2009;19(9):634–40.

    Article  PubMed  Google Scholar 

  43. de Simone G, Devereux RB, Izzo R, Girfoglio D, Lee ET, Howard BV, et al. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study. J Am Heart Assoc. 2013;2(3):e000144.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Babazono T, Takahashi C, Iwamoto Y. Definition of microalbuminuria in first-morning and random spot urine in diabetic patients. Diabetes Care. 2004;27(7):1838–9.

    Article  PubMed  Google Scholar 

  45. Pontremoli R, Leoncini G, Ravera M, Viazzi F, Vettoretti S, Ratto E, et al. Microalbuminuria, cardiovascular, and renal risk in primary hypertension. J Am Soc Nephrol. 2002;13 Suppl 3:S169–72.

    Article  CAS  PubMed  Google Scholar 

  46. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000;35(4):898–903.

    Article  CAS  PubMed  Google Scholar 

  47. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–6.

    Article  CAS  PubMed  Google Scholar 

  48. Stuveling EM, Bakker SJ, Hillege HL, Burgerhof JG, de Jong PE, Gans RO, et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension. 2004;43(4):791–6.

    Article  CAS  PubMed  Google Scholar 

  49. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2002;22(4):593–8.

    Article  CAS  PubMed  Google Scholar 

  50. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 1995;273(20):1592–7.

    Article  CAS  PubMed  Google Scholar 

  51. de Simone G, Muiesan ML, Ganau A, Longhini C, Verdecchia P, Palmieri V, et al. Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients: the RES trial. Working Group on Heart and Hypertension of the Italian Society of Hypertension. Reliability of M-mode Echocardiographic Studies. J Hypertens. 1999;17(12 Pt 2):1955–63.

    Article  PubMed  Google Scholar 

  52. de Simone G, Izzo R, Chinali M, De Marco M, Casalnuovo G, Rozza F, et al. Does information on systolic and diastolic function improve prediction of a cardiovascular event by left ventricular hypertrophy in arterial hypertension? Hypertension. 2010;56(1):99–104.

    Article  PubMed  Google Scholar 

  53. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14–22.

    Article  PubMed  Google Scholar 

  54. Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009;120(12):1084–90.

    Article  PubMed  Google Scholar 

  55. Moreno PR, Kini A. Resolution of inflammation, statins, and plaque regression. J Am Coll Cardiol Img. 2012;5(2):178–81.

    Article  Google Scholar 

  56. Ibanez B, Vilahur G, Badimon JJ. Plaque progression and regression in atherothrombosis. J Thromb Haemost. 2007;5 Suppl 1:292–9.

    Article  CAS  PubMed  Google Scholar 

  57. Zellweger MJ, Weinbacher M, Zutter AW, Jeger RV, Mueller-Brand J, Kaiser C, et al. Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. J Am Coll Cardiol. 2003;42(1):33–40.

    Article  PubMed  Google Scholar 

  58. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol. 1997;30(1):260–311.

    Article  CAS  PubMed  Google Scholar 

  59. Marwick TH, Torelli J, Harjai K, Haluska B, Pashkow FJ, Stewart WJ, et al. Influence of left ventricular hypertrophy on detection of coronary artery disease using exercise echocardiography. J Am Coll Cardiol. 1995;26(5):1180–6.

    Article  CAS  PubMed  Google Scholar 

  60. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation. 2002;106(14):1883–92.

    Article  PubMed  Google Scholar 

  61. Marwick TH, Gillebert TC, Aurigemma G, Chirinos J, Derumeaux G, Galderisi M, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)dagger. Eur Heart J Cardiovasc Imaging. 2015;16(6):577–605.

    PubMed  Google Scholar 

  62. Pingitore A, Picano E, Varga A, Gigli G, Cortigiani L, Previtali M, et al. Prognostic value of pharmacological stress echocardiography in patients with known or suspected coronary artery disease: a prospective, large-scale, multicenter, head-to-head comparison between dipyridamole and dobutamine test. Echo-Persantine International Cooperative (EPIC) and Echo-Dobutamine International Cooperative (EDIC) Study Groups. J Am Coll Cardiol. 1999;34(6):1769–77.

    Article  CAS  PubMed  Google Scholar 

  63. de Simone G, Parati G. Imaging techniques for non-invasive assessment of coronary heart disease in hypertension: value of an integrated approach. J Hypertens. 2001;19(4):679–82.

    Article  PubMed  Google Scholar 

  64. Galderisi M, de Simone G, D’Errico A, Sidiropulos M, Viceconti R, Chinali M, et al. Independent association of coronary flow reserve with left ventricular relaxation and filling pressure in arterial hypertension. Am J Hypertens. 2008;21(9):1040–6.

    Article  PubMed  Google Scholar 

  65. Cortigiani L, Rigo F, Gherardi S, Sicari R, Galderisi M, Bovenzi F, et al. Additional prognostic value of coronary flow reserve in diabetic and nondiabetic patients with negative dipyridamole stress echocardiography by wall motion criteria. J Am Coll Cardiol. 2007;50(14):1354–61.

    Article  PubMed  Google Scholar 

  66. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130(19):1749–67.

    Article  PubMed  Google Scholar 

  67. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;121(22):2509–43.

    Article  PubMed  Google Scholar 

  68. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52.

    Article  PubMed  Google Scholar 

  69. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.

    Article  CAS  PubMed  Google Scholar 

  70. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.

    Article  CAS  PubMed  Google Scholar 

  71. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–209.

    Article  PubMed  Google Scholar 

  72. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260–9.

    Article  CAS  PubMed  Google Scholar 

  73. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.

    Article  CAS  PubMed  Google Scholar 

  74. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010;121(12):1393–405.

    Article  PubMed  Google Scholar 

  75. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.

    Google Scholar 

  76. Carson P, Tognoni G, Cohn JN. Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail. 2003;9(3):164–71.

    Article  CAS  PubMed  Google Scholar 

  77. Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail. 2009;11(1):68–76.

    Article  CAS  PubMed  Google Scholar 

  78. Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158(3):422–30.

    Article  CAS  PubMed  Google Scholar 

  79. Ferrandis MJ, Ryden I, Lindahl TL, Larsson A. Ruling out cardiac failure: cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography. Ups J Med Sci. 2013;118(2):75–9.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol. 2003;92(12):1434–8.

    Article  CAS  PubMed  Google Scholar 

  81. Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26(21):2277–84.

    Article  PubMed  Google Scholar 

  82. Dahlstrom U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail. 2004;6(3):281–7.

    Article  CAS  PubMed  Google Scholar 

  83. Staessen JA, Kuznetsova T, Stolarz K. Hypertension prevalence and stroke mortality across populations. JAMA. 2003;289(18):2420–2.

    Article  PubMed  Google Scholar 

  84. Esenwa C, Gutierrez J. Secondary stroke prevention: challenges and solutions. Vasc Health Risk Manag. 2015;11:437–50.

    Google Scholar 

  85. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–236.

    Article  PubMed  Google Scholar 

  86. Aiyagari V, Gorelick PB. Management of blood pressure for acute and recurrent stroke. Stroke. 2009;40(6):2251–6.

    Article  PubMed  Google Scholar 

  87. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382(9891):507–15.

    Article  CAS  PubMed  Google Scholar 

  88. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4.

    Article  CAS  PubMed  Google Scholar 

  89. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(14):1501–8.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Losi MA, Izzo R, De Marco M, Canciello G, Rapacciuolo A, Trimarco V, et al. Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network. Int J Cardiol. 2015;199:290–5.

    Google Scholar 

  91. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54(5):1084–91.

    Article  CAS  PubMed  Google Scholar 

  92. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–41.

    Google Scholar 

  93. Mitchell LB, Southern DA, Galbraith D, Ghali WA, Knudtson M, Wilton SB. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart. 2014;100(19):1524–30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Research Center, FEDERICO II University Naples, Naples, Italy

    Carmine Morisco M.D., Bruno Trimarco M.D. & Giovanni de Simone M.D., FESC, FACC, FAHA

Authors
  1. Carmine Morisco M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Trimarco M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni de Simone M.D., FESC, FACC, FAHA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni de Simone M.D., FESC, FACC, FAHA .

Editor information

Editors and Affiliations

  1. Fourth Internal Medicine Department, Evangelismos State General Hospital, Athens, Greece

    Emmanuel A. Andreadis

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Morisco, C., Trimarco, B., de Simone, G. (2016). Follow-Up of the Hypertensive Patients with Cardiovascular Disease. In: Andreadis, E. (eds) Hypertension and Cardiovascular Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-39599-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-39599-9_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-39597-5

  • Online ISBN: 978-3-319-39599-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation